临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Clevudine
中文名称:克拉夫定
CAS号:163252-36-6
分子式: C10H13FN2O5 分子量: 260.22
产品形式: free base
研发状态: Terminated
研发用途: Chronic Hepatitis b
研究机构: Antios Therapeutics Inc
研发日期: March 29 2022
研发阶段: Phase 1
Clevudine(Levovir,L-FMAU) is an antiviral drug for the treatment of hepatitis B.
Namodenoson (CF-102)
中文名称:氯-IB-MECA
CAS号:163042-96-4
分子式: C18H18ClIN6O4 分子量: 544.73
产品形式: Free Base
研发状态: Recruiting
研发用途: Hepatocellular Carcinoma; Cirrhosis
研究机构: Can-Fite BioPharma
研发日期: March 15 2023
研发阶段: Phase 3
Namodenoson (CF-102, 2-Cl-IB-MECA) is an orally bioavailable and selective agonist of the A3 adenosine receptor (A3AR) with Ki of 0.33 nM. Namodenoson exerts an anti‑NASH effect mediated via the de‑regulation of the PI3K/NF‑κB/Wnt/β‑catenin signaling pathway.
Fezolinetant
中文名称:非唑奈坦
CAS号:1629229-37-3
分子式: C₁₆H₁₅FN₆OS 分子量: 358.39
产品形式: free base
研发状态: Recruiting
研发用途: Hot Flashes
研究机构: Astellas Pharma Inc
研发日期: February 22 2024
研发阶段: Phase 3
Fezolinetant (ESN-364) is a potential antagonist of the neurokinin 3 receptor (NK3R). It interrupts pulsatile lh secretion and moderates levels of ovarian hormones throughout the menstrual cycle.
Itacnosertib (TP-0184)
CAS号:1628870-27-8
分子式: C26H28N8O 分子量: 468.55
产品形式: free base
研发状态: Terminated
研发用途: Anemia in Myelodysplastic Syndromes
研究机构: Sumitomo Pharma America Inc.
研发日期: December 28 2020
研发阶段: Phase 1 : Phase 2
Itacnosertib (TP-0184) is a small-molecule inhibitor of the BMP type 1 receptor ALK2 (also known as ACVR1). Itacnosertib reduces hepcidin induction and elevated serum iron levels in turpentine and lung cancer mouse models of ACD.
Vimseltinib
CAS号:1628606-05-2
分子式: C23H25N7O2 分子量: 431.49
产品形式: Free base
研发状态: Active not recruiting
研发用途: Advanced Malignant Neoplasm; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor; Tenosynovial Giant Cell Tumor Diffuse
研究机构: Deciphera Pharmaceuticals LLC
研发日期: February 16 2017
研发阶段: Phase 1 : Phase 2
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively.
LY3143921 hydrate
中文名称:(3S)-3-(5-氟嘧啶-4-基)-3-甲基-6-(1H-吡氮卓-4-基)-2H-异哧啶-1-1水合物
CAS号:1627696-53-0
分子式: C16H14FN5O2 分子量: 327.31
产品形式: Hydrate
研发状态: Active not recruiting
研发用途: a. Colorectal Cancer; b. High Grade Serous Ovarian Cancer; c. Non Small-cell Lung Cancer (Squamous Cell Variant); d. Squamous Carcinoma of the Oesophagus; e. Squamous Carcinoma of the Head and Neck (HPV Negative); f. Urothelial Cancer; g. Breast Cancer (Triple Negative Type); h. Pancreatic Cancer
研究机构: Cancer Research UK
研发日期: June 21 2017
研发阶段: Phase 1
LY3143921 hydrate is an orally administered ATP-competitive CDC7 inhibitor.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
